23866-72-0

Basic information

• Product Name: ETHYL 7-HYDROXY-4-OXO-4H-CHROMENE-2-CARBOXYLATE
• Synonyms: ETHYL 7-HYDROXY-4-OXO-4H-CHROMENE-2-CARBOXYLATE;Ethyl 7-hydroxy-4-oxo-4H-chromene-2-carboxylate 97%;ethyl 7-hydroxy-4-oxo-4H-chromen-2-carboxylate;Ethyl7-hydroxy-4-oxo-4H-chromene-2-carboxylate97%;7-Hydroxy-4-oxo-4H-1-benzopyran-2-carboxylic acid ethyl ester;Ethyl 7-hydroxy-4-oxo-4H-1-benzopyran-2-carboxylate 97%;Ethyl 7-hydroxy-4-oxo-4H-chromene-2-carboxylate, 2-(Ethoxycarbonyl)-7-hydroxy-4-oxo-4H-1-benzopyran;Ethyl7-hydroxy-4-oxo-4H-1-benzopyran-2-carboxylate97%
• CAS NO: 23866-72-0
• Molecular Formula: C₁₂H₁₀O₅
• Molecular Weight: 234.2
• Mol File: 23866-72-0.mol
• Article Data: 18

Chemical Properties

• Melting Point: 222 °C
• Boiling Point: 408.6°Cat760mmHg
• Flash Point: 161.2°C
• Appearance: /
• Density: 1.397g/cm³
• Vapor Pressure: 2.93E-07mmHg at 25°C
• Refractive Index: 1.598
• CAS DataBase Reference: ETHYL 7-HYDROXY-4-OXO-4H-CHROMENE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 7-HYDROXY-4-OXO-4H-CHROMENE-2-CARBOXYLATE(23866-72-0)
• EPA Substance Registry System: ETHYL 7-HYDROXY-4-OXO-4H-CHROMENE-2-CARBOXYLATE(23866-72-0)

Safety Data

• Hazard Codes: Xi
• Safety Statements: S24/25:Avoid contact with skin and eyes.
• Hazardous Substances Data: 23866-72-0(Hazardous Substances Data)

Usage

Description

ETHYL 7-HYDROXY-4-OXO-4H-CHROMENE-2-CARBOXYLATE, a chemical compound with the molecular formula C13H10O5, is a derivative of 4H-chromene. It is recognized for its potential biological activities, such as anti-inflammatory and antioxidant properties, and is a subject of interest in organic synthesis and pharmaceutical research. This promising compound is being explored for its role in the development of new drugs and therapeutic agents, indicating its significance in the fields of medicine and chemical research.

Uses

Used in Pharmaceutical Research:
ETHYL 7-HYDROXY-4-OXO-4H-CHROMENE-2-CARBOXYLATE is used as a key intermediate in the synthesis of various pharmaceutical compounds due to its unique chemical structure and potential biological activities.
Used in Organic Synthesis:
In the field of organic synthesis, ETHYL 7-HYDROXY-4-OXO-4H-CHROMENE-2-CARBOXYLATE serves as a valuable building block for the creation of complex organic molecules, contributing to the advancement of chemical science.
Used in Drug Development:
ETHYL 7-HYDROXY-4-OXO-4H-CHROMENE-2-CARBOXYLATE is utilized as a potential active pharmaceutical ingredient in the development of new drugs, particularly those targeting inflammation and oxidative stress-related conditions, owing to its anti-inflammatory and antioxidant properties.
Used in Therapeutic Agent Development:
ETHYL 7-HYDROXY-4-OXO-4H-CHROMENE-2-CARBOXYLATE is being investigated for its potential as a therapeutic agent in medicine, with ongoing research focusing on its ability to modulate biological processes and treat specific diseases or conditions.
Used in Chemical Research:
ETHYL 7-HYDROXY-4-OXO-4H-CHROMENE-2-CARBOXYLATE is employed in chemical research to study its reactivity, stability, and interactions with other molecules, which can lead to a better understanding of its properties and potential applications.

InChI:InChI=1/C12H10O5/c1-2-16-12(15)11-6-9(14)8-4-3-7(13)5-10(8)17-11/h3-6,13H,2H2,1H3

Upstream product

• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 60-29-7 diethyl ether 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 38322-74-6 7-methoxy-4-oxo-4H-chromene-2-carboxylic acid ethyl ester 
• 30113-83-8 7-hydroxy-4-oxo-4H-chromene-2-carboxylic acid 
• 180716-16-9 3,4-dihydro-7-(phenylmethoxy)-2H-1-benzopyran-2-methanol 
• 1309652-23-0 7-benzyloxy-2-ethoxymethyl-chroman 
• 96565-55-8 (R,S)-6-acetyl-7-<<5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyl>oxy>-3,4-dihydro-2H-H-benzopyran-2-carboxylic acid sodium salt 
• 120329-95-5 methyl (R,S)-6-acetyl-7-<5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy>-3,4-dihydro-2H-1-benzopyran-2-carboxylate 
• 96614-75-4 <2R-<2α(1R*,2R*)>>-6-acetyl-7-<<5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyl>oxy>-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid 2-hydroxy-1-methylpropyl ester 
• 96566-42-6 <2S-<2β(1R*,2R*)>>-6-acetyl-7-<<5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyl>oxy>-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid 2-hydroxy-1-methylpropyl ester 
• 96686-73-6 R-(-)-6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyloxy]-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid 
• 96686-71-4 (S)-(+)-6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyloxy]-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid 
• 96566-53-9 6-Acetyl-7-[6-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-hexyloxy]-chroman-2-carboxylic acid ethyl ester 
• 96566-61-9 8-Acetyl-7-[5-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-pentyloxy]-chroman-2-carboxylic acid methyl ester 
• 96566-55-1 6-Acetyl-7-[4-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-butoxy]-chroman-2-carboxylic acid ethyl ester 

Relevant articles and documents

Chromone derivatives bearing pyridinium moiety as multi-target-directed ligands against Alzheimer's disease

A new serise of 7-hydroxy-chromone derivatives bearing pyridine moiety were synthesized, and evaluated as multifunctional agents against Alzheimer's disease (AD). Most of the compounds were good AChE inhibitors (IC50 = 9.8–0.71 μM) and showed remarkable BuChE inhibition activity (IC50 = 1.9–0.006 μM) compared with donepezil as the standard drug (IC50 = 0.023 and 3.4 μM). Compounds 14 and 10 showed the best inhibitory activity toward AChE (IC50 = 0.71 μM) and BuChE (IC50 = 0.006 μM), respectively. The ligand–protein docking simulations and kinetic studies revealed that compound 14 and 10 could bind effectively to the peripheral anionic binding site (PAS) of the AChE and BuChE through mixed-type inhibition. In addition, the most potent compounds showed acceptable neuroprotective activity on H2O2- and Aβ-induced.neurotoxicity in PC12 cells, more than standard drugs. The compounds could block effectively self- and AChE-induced Aβ aggregation. All the results suggest that compounds 14 and 10 could be considered as promising multi-target-directed ligands against AD.

Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles

GPR40 has become a new potential therapeutic target for the treatment of diabetes due to its role in mediating the enhancement of glucose-stimulated insulin secretion in pancreatic β cells with a low risk of hypoglycemia. As an effort to extend the chemical space and identify structurally distinct GPR40 agonists with improved liver safety, a novel series of fused-ring phenyl propanoic acid analogues were designed. Comprehensive structure-activity relationship studies around novel scaffolds were conducted and led to several analogues exhibited potent GPR40 agonistic activities and high selectivity against other fatty acid receptors. Further evaluation of pharmacokinetic (PK) profiles and in vivo efficacy identified compound 40a with excellent PK properties and significant glucose-lowering efficacy during an oral glucose tolerance test. In addition, compound 40a displayed lower hepatobiliary transporter inhibition and favorable druggability. All results indicate that compound 40a is a promising candidate for further development.

ANTI-INFECTIVE AGENTS

The present invention relates to a novel class of chromene-2-carboxamide compounds inhibitors of general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and their use as anti-infective agents in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.